To our knowledge, this is the first study demonstrating that hypopituitarism is independently associated with an increased risk of DA resistance in patients treated with cabergoline in bioactive macroprolactinoma with PRL ≥ 1000 ng/mL. Here, PRL is linked to hypopituitarism.